Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity
ABSTRACT Background Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR‐APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western pati...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.13595 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850051216216686592 |
|---|---|
| author | Pauline Parent Frédéric Pigneur Marc Hilmi Aurélien Carnot Marie‐Line Garcia Larnicol Dewi Vernerey Alain Luciani Pascal Hammel Julie Henriques Cindy Neuzillet Anthony Turpin |
| author_facet | Pauline Parent Frédéric Pigneur Marc Hilmi Aurélien Carnot Marie‐Line Garcia Larnicol Dewi Vernerey Alain Luciani Pascal Hammel Julie Henriques Cindy Neuzillet Anthony Turpin |
| author_sort | Pauline Parent |
| collection | DOAJ |
| description | ABSTRACT Background Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR‐APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western patients receiving first‐line chemotherapy. The study aimed to assess (1) the potential impact of computed tomography (CT)–quantified muscle mass before and during treatments on health‐related quality of life (HRQoL) and overall survival (OS) and (2) the role of APA in mitigating muscle mass loss. Methods In the APACaP trial, aPDAC patients with ECOG performance status (PS) 0–2 were randomized 1:1 to usual care including first‐line chemotherapy or usual care plus a 16‐week home‐based APA program. In the SarcAPACaP study, the surface muscular index (SMI) was determined from L3 CT scan slices. Two patient populations were analysed: those with CT scan available at baseline (modified[m] intent‐to‐treat [ITT]1‐W0) and those with CT scans available at both W0 and W16 (mITT2 W0–W16). Low muscle mass was defined by low SMI with SMI < 41 cm2/m2 for women and < 43 and < 53 cm2/m2 for men with body max index < 25.0 and ≥ 25.0 kg/m2, respectively. Muscle loss was defined by the relative difference of SMI between W0 and W16 (100*[SMI W16–SMI W0]/SMI W0). In mITT2 W0–W16, patients were stratified into three groups based on the severity of muscle loss: none, moderate (0%–10%) and high (≥ 10%). Associations between muscle mass loss and OS, time until definitive deterioration (TUDD) of HRQoL and the effect of APA on loss of muscle mass were assessed. Results Between October 2014 and May 2020, 313 patients were prospectively enrolled, with 225 in mITT1 W0 and 128 in mITT2 W0–W16, with 65 assigned to the APA arm. Both groups had similar baseline characteristics with comparable OS and TUDD. A low SMI at W0 was not associated with OS and TUDD of HRQoL in either group. Among mITT2 W0–W16 patients, high muscle mass loss (n = 27) independently predicted OS (p = 0.012) and showed a trend toward negatively affecting TUDD of HRQoL. Notably, APA did not mitigate muscle loss in our study population. Conclusions Longitudinal muscle mass loss emerged as a predictive factor for both OS and HRQoL in aPDAC patients undergoing chemotherapy, while a low SMI at diagnosis did not provide prognostic value. APA did not impact muscle mass loss in this population. |
| format | Article |
| id | doaj-art-849376abfc174376a0dc334d495f691e |
| institution | DOAJ |
| issn | 2190-5991 2190-6009 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Cachexia, Sarcopenia and Muscle |
| spelling | doaj-art-849376abfc174376a0dc334d495f691e2025-08-20T02:53:13ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092025-02-01161n/an/a10.1002/jcsm.13595Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical ActivityPauline Parent0Frédéric Pigneur1Marc Hilmi2Aurélien Carnot3Marie‐Line Garcia Larnicol4Dewi Vernerey5Alain Luciani6Pascal Hammel7Julie Henriques8Cindy Neuzillet9Anthony Turpin10Department of Medical Oncology Lille University Hospital Lille FranceDepartment of Radiology, Henri Mondor Hospital, AP‐HP University of Paris Est, UPEC Créteil FranceDepartment of Medical Oncology, Institute Curie Université Versailles Saint‐Quentin, Paris Saclay Saint‐Cloud FranceDepartment of Medical Oncology Centre Oscar Lambret Lille FranceGERCOR Paris FranceMethodology and Quality of Life Unit in Oncology University of Besancon Besançon FranceDepartment of Radiology, Henri Mondor Hospital, AP‐HP University of Paris Est, UPEC Créteil FranceDepartment of Digestive and Medical Oncology, Paul Brousse Hospital University Paris‐Saclay Villejuif FranceMethodology and Quality of Life Unit in Oncology University of Besancon Besançon FranceDepartment of Medical Oncology, Institute Curie Université Versailles Saint‐Quentin, Paris Saclay Saint‐Cloud FranceDepartment of Medical Oncology Lille University Hospital Lille FranceABSTRACT Background Advanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR‐APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western patients receiving first‐line chemotherapy. The study aimed to assess (1) the potential impact of computed tomography (CT)–quantified muscle mass before and during treatments on health‐related quality of life (HRQoL) and overall survival (OS) and (2) the role of APA in mitigating muscle mass loss. Methods In the APACaP trial, aPDAC patients with ECOG performance status (PS) 0–2 were randomized 1:1 to usual care including first‐line chemotherapy or usual care plus a 16‐week home‐based APA program. In the SarcAPACaP study, the surface muscular index (SMI) was determined from L3 CT scan slices. Two patient populations were analysed: those with CT scan available at baseline (modified[m] intent‐to‐treat [ITT]1‐W0) and those with CT scans available at both W0 and W16 (mITT2 W0–W16). Low muscle mass was defined by low SMI with SMI < 41 cm2/m2 for women and < 43 and < 53 cm2/m2 for men with body max index < 25.0 and ≥ 25.0 kg/m2, respectively. Muscle loss was defined by the relative difference of SMI between W0 and W16 (100*[SMI W16–SMI W0]/SMI W0). In mITT2 W0–W16, patients were stratified into three groups based on the severity of muscle loss: none, moderate (0%–10%) and high (≥ 10%). Associations between muscle mass loss and OS, time until definitive deterioration (TUDD) of HRQoL and the effect of APA on loss of muscle mass were assessed. Results Between October 2014 and May 2020, 313 patients were prospectively enrolled, with 225 in mITT1 W0 and 128 in mITT2 W0–W16, with 65 assigned to the APA arm. Both groups had similar baseline characteristics with comparable OS and TUDD. A low SMI at W0 was not associated with OS and TUDD of HRQoL in either group. Among mITT2 W0–W16 patients, high muscle mass loss (n = 27) independently predicted OS (p = 0.012) and showed a trend toward negatively affecting TUDD of HRQoL. Notably, APA did not mitigate muscle loss in our study population. Conclusions Longitudinal muscle mass loss emerged as a predictive factor for both OS and HRQoL in aPDAC patients undergoing chemotherapy, while a low SMI at diagnosis did not provide prognostic value. APA did not impact muscle mass loss in this population.https://doi.org/10.1002/jcsm.13595adapted physical activityCT scanmuscular mass losspancreatic cancerquality of lifesarcopenia |
| spellingShingle | Pauline Parent Frédéric Pigneur Marc Hilmi Aurélien Carnot Marie‐Line Garcia Larnicol Dewi Vernerey Alain Luciani Pascal Hammel Julie Henriques Cindy Neuzillet Anthony Turpin Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity Journal of Cachexia, Sarcopenia and Muscle adapted physical activity CT scan muscular mass loss pancreatic cancer quality of life sarcopenia |
| title | Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity |
| title_full | Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity |
| title_fullStr | Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity |
| title_full_unstemmed | Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity |
| title_short | Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity |
| title_sort | muscle loss during first line chemotherapy impairs survival in advanced pancreatic cancer despite adapted physical activity |
| topic | adapted physical activity CT scan muscular mass loss pancreatic cancer quality of life sarcopenia |
| url | https://doi.org/10.1002/jcsm.13595 |
| work_keys_str_mv | AT paulineparent musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT fredericpigneur musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT marchilmi musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT aureliencarnot musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT marielinegarcialarnicol musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT dewivernerey musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT alainluciani musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT pascalhammel musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT juliehenriques musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT cindyneuzillet musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity AT anthonyturpin musclelossduringfirstlinechemotherapyimpairssurvivalinadvancedpancreaticcancerdespiteadaptedphysicalactivity |